Pharmaceuticals
CN Energy Signs Operation & Management Agreement; Enters Multi-Billion Dollar Pharmaceutical Excipients Market
LISHUI, China, Jan. 18, 2022 /PRNewswire/ -- CN Energy Group. Inc. (the "Company") today announced that its subsidiary Hangzhou Forasen Technology Co., Ltd. signed an operation and management ("O&M") agreement (the "Agreement") with HuaiNan JiaHe New Materials Co., Ltd. ("JiaHe") and JiaHe's acti...
2022-01-18 21:00
2532
Servier Group Reports Financial Year 2020/2021 Annual Results, R&D Strategy and Pipeline
- Consolidated revenue of €4.725 billion, up +4.3% at constant rates (+0.8% at current rates) - Revenue for brand-name medicines of €3.306 billion +4.8% at constant rates (+0.6% at current rates) and €1.419 billion for the generics +2.9% at constant rates (+1.1% at current rates) - An accelerat...
2022-01-18 20:00
2758
Ascletis Announces Signing of Ritonavir Tablet Purchase Agreement with Phokam Pharmaceutical Import-Export Co., Ltd of Laos
HANGZHOU and SHAOXING, China, Jan. 18, 2022 /PRNewswire/ -- Ascletis Pharma Inc. ("Ascletis") (HKEX: 1672) today announces signing of the ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export Co., Ltd (as buyer) ofLaos and Ascletis Pharmaceuticals Co., Ltd. (as seller), ...
2022-01-18 18:00
3921
MindRank Begins IND-enabling Studies of its first AI-designed Drug, 8 Months After Program Initiation
HANGZHOU, China, Jan. 18, 2022 /PRNewswire/ -- MindRank AI, an artificial intelligence (AI) driven biotech company, today announced that the company has nominated a preclinical candidate (PCC) for an important class B GPCR drug target, 8 Months After Program Initiation. Historically, the developm...
2022-01-18 17:17
2308
Dermaliq Therapeutics Signs USD 15 Million Series A Round to Advance Three Transformative Drug Therapies into Clinical Trials
WILMINGTON, Del., Jan. 18, 2022 /PRNewswire/ -- Novaliq GmbH, 3E Bioventures Capital and Beijing Whale Technology Corporation Ltd. today announced the establishment of Dermaliq Therapeutics, Inc (Dermaliq), a newly formedDelaware -based pharmaceutical development company, and the signing of aUSD 1...
2022-01-18 17:00
3088
InnoCare and Keymed Jointly Announce Dosing of First Patient in Clinical Trial of CD20xCD3 Bispecific Antibody CM355
BEIJING, Jan. 18, 2022 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) and Keymed Biosciences (HKEX: 02162) jointly announced today that the first patient inChina has been dosed in clinical trial of CM355, a CD20xCD3 bispecific antibody developed by a joint venture between the two companies, for th...
2022-01-18 14:51
2972
Baheya Foundation, Egypt's Premier Destination for Breast Cancer, Adopts Lunit AI to Enhance Early Screening
SEOUL, South Korea, Jan. 18, 2022 /PRNewswire/ -- Lunit today announced a Reference Site Agreement with Baheya Foundation for Early Detection & Treatment of Breast Cancer, a non-profit organization based inEgypt that treats women with breast cancer. According to the agreement, the foundation will...
2022-01-18 13:00
2541
WuXi Biologics Completes GMP Inspection by South Korea's Ministry of Food and Drug Safety for Drug Substance Facility
* WuXi Biologics completes the first GMP inspection in 2022, demonstrating the company's premier quality system is in full compliance with global regulatory requirements. WUXI, China, Jan. 17, 2022 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access ...
2022-01-18 10:50
2884
CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment
* Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in patients with metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC) * A significant milestone in our pipeline development...
2022-01-18 08:00
5310
Sciwind Biosciences Announces Initiation of Patient Dosing in Phase 2b Clinical Trial Evaluating XW003, its Lead GLP-1 Drug Candidate, for the Treatment of Obesity
HANGZHOU, China and SAN FRANCISCO, Jan. 18, 2022 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, today announced the initiation of patient dosing in its Phase2b clinica...
2022-01-18 08:00
4231
CARsgen Appoints Richard John Daly as the President of CARsgen Therapeutics Corporation
SHANGHAI and DURHAM, N.C., Jan. 17, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company mainly focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today the appointment ofRichard John Daly ("M...
2022-01-17 21:50
3312
Seegene Continues to Support Israel's Effort to Manage the Omicron Variant With Timely Delivery of Five Million Tests
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, announced today that it has delivered over five million COVID-19 tests toIsrael to help detect and mitigate the spread of the Omicron variant. The company sent 1.7 mill...
2022-01-17 20:00
3339
Seegene's Allplex™ SARS CoV-2 FluA/FluB/RSV Assay approved under Health Canada's Interim Order
SEOUL, South Korea, Jan. 17, 2022 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostic company, announced it has received approval of its Allplex™ SARS CoV-2 FluA/FluB/RSV Assay under Health Canada's Interim Order onJanuary 11. Seegene's Allplex™ SARS CoV-2 Flu...
2022-01-17 20:00
3528
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B
-- Estimated 1.59 million chronic hepatitis B (CHB) patients in the U.S. -- Interim results of the Phase IIb trial conducted on CHB patients in China showed that in patients with the baseline hepatitis B surface antigen (HBsAg) level ≤ 500 IU/mL, approximately 19% (3/16) of patients in the treatm...
2022-01-17 18:12
5283
The Philippines Has Approved ReCOV For Phase II/III Cinical Trial
* Recombinant Two-Component COVID-19 Vaccine (ReCOV) was approved for International Phase II/III Clinical Trial * ReCOV induced high levels of neutralizing antibodies against SARS-CoV-2 and Variants of Concern such as Omicron and Delta * Rhecogen , a subsidiary focused on mRNA vaccines of th...
2022-01-17 16:57
3976
Green Valley Obtains IND Approval from U.S. FDA for Sodium Oligomannate's Global Phase II Clinical Trial in Treating Parkinson's Disease
SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- On January 13, 2022, Green Valley ( Shanghai) Pharmaceuticals Co., Ltd. received the letter from the US Food and Drug Administration (FDA) on the Investigational New Drug (IND) application for the global multi-center phase-II clinical trial of Oligomannate (...
2022-01-17 14:29
1769
Jacobio Receives IND Approval for Aurora A Inhibitor JAB-2485 from FDA
BEIJING and SHANGHAI and BOSTON, Jan. 16, 2022 /PRNewswire/ -- Jacobio's self-developed global first-in-class drug Aurora A inhibitor JAB-2485 received IND (Investigational New Drug) from the FDA (Food and Drug Administration) in US. Jacobio plans to initiate a Phase I/IIa clinical trial in pati...
2022-01-17 09:04
1947
CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that the registrational clinical...
2022-01-15 08:35
7095
CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology
SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and precision medicines, today announced that results of the GEMSTONE-302...
2022-01-15 08:31
6450
French Consul General in Guangzhou led a delegation to visit Biosyngen in China-Singapore Guangzhou Knowledge City
GUANGZHOU, ChinaJan. 15, 2022 /PRNewswire/ -- On the afternoon of January 14th, Mr. Sylvain FOURRIERE, Consul General ofFrance in Guangzhou, and officers from consulates general of 9 countries includingBritain, Canada and Switzerland visited China-Singapore Guangzhou Knowledge City andSingapore -...
2022-01-15 08:00
7178
Week's Top Stories
Most Reposted
Visa and Marina Bay Precinct Partners - Marina Bay Sands, UOB and Singapore Tourism Board - Present 'A Moment to Savour', Bringing International Restaurant Collaborations to Singapore
[Picked up by 310 media titles]
2026-10-27 13:40
Hong Leong Bank Strengthens Cross-Border Payment Connectivity through Partnership with UnionPay International
[Picked up by 294 media titles]
2026-10-28 12:12
Agoda becomes first travel platform regionally to seamlessly connect with Meta's Muse
[Picked up by 294 media titles]
2026-10-28 09:00
OneQode Signs 14 MW AI Capacity Agreement with AdaniConneX, with a Path to 114 MW
[Picked up by 277 media titles]
2026-10-28 09:00
Pepperstone and Aston Martin Aramco extend and expand partnership with Fernando Alonso appointed Global Ambassador from 2027.
[Picked up by 276 media titles]
2026-10-29 13:01
Most Read
1B views since June: Coda and TikTok Gaming turn content into commerce
2026-11-02 09:35
52348
SwitchBot Launches AI Art Frame 2 with Full-Color E Ink and Personalized Art
2026-10-27 21:00
51309
